CNR1 and Alzheimer disease: Topical CB1R agonist, α- oleoyl oleyl amine serinol, showed a statistically significant recovery of epidermal permeability barrier (p < 0.01) and reduced epidermal hyperplasia in an AD mouse model whereas mice who lacked CB1R showed decreased epidermal barrier recovery and increased ear swelling [70].